Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL)

Whole-Body Positron Emission Tomography Using18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin’s Disease and Non-Hodgkin’s Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging

Guy Jérusalem, Yves Béguin, Marie‐France Fassotte et al. · Blood · 1999 · 556 citations

Medicine, Nuclear Medicine, Oncology +16

Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.

Wolfgang Römer, Axel-R. Hanauske, Sibylle Ziegler et al. · PubMed · 1998 · 338 citations

Medicine, Oncology, Radiology +10

Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.

Florian Moog, Markus Bangerter, C. G. Diederichs et al. · Radiology · 1997 · 312 citations

Medicine, Nuclear Medicine, Radiology +15

Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.

Joel S. Newman, Isaac R. Francis, Mark Kaminski et al. · Radiology · 1994 · 267 citations

Medicine, Nuclear Medicine, Radiology +17

Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography

Katrin D. M. Stumpe, M. Urbinelli, Hans C. Steinert et al. · European Journal of Nuclear Medicine and Molecular Imaging · 1998 · 264 citations

Medicine, Nuclear Medicine, Oncology +12